Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 14, 2025
National Trans Visibility March to Honor NMAC’s Paul Kawata with Lifetime Allyship & Justice Award
EIN Presswire
·
May 14, 2025
WASHINGTON, DC, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- The National Trans Visibility March (NTVM) is honored to announce that Paul Kawata, the esteemed Executive Director of NMAC, will receive the organization’s highest honor: the Lifetime …
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
GlobeNewswire
·
May 14, 2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 …
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from …
Precipio Announces its Q1-2025 Financial Results
GlobeNewswire
·
May 14, 2025
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain …
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting …
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
GlobeNewswire
·
May 14, 2025
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: …
Radical Truths Summit to Address Global Trends in Surveillance, Psychological Manipulation, and Public Autonomy
EIN Presswire
·
May 14, 2025
Virtual event to feature international experts, researchers, and targeted survivors May 21 – June 3, 2025 NA, TX, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- From concerns over digital privacy to the rise in reported psychological coercion and …
SS Innovations Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “ …
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire
·
May 14, 2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the lives of …
Jasper Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
GlobeNewswire
·
May 14, 2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
GlobeNewswire
·
May 14, 2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to …
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean …
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
GlobeNewswire
·
May 14, 2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the …
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in …
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
GlobeNewswire
·
May 14, 2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …